Shinpoong Makes Exclusive Licensing Agreement for Tesmilifene

Published: 2005-02-01 06:56:00

Updated: 2005-02-01 06:56:00

Shinpoong Pharmaceutical Co. Ltd. announced last week that it made an exclusive domestic licensing agreement with YM BioSciences Inc.'s tesmilifene, a novel anticancer agent currently undergoing a multinational phase III clinical trial in patients with advanced breast cancer.

Discovered and developed by YM BioSciences, a Canadian pharmaceutical company specialized in the development of c...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.